exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088175 RNA Name: hsa-miR-338-3p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 81125887 End Site(bp): 81125908 External Links: hsa-miR-338-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ADCY9 chr16 3953387 4116442 - ARPC1B chr7 99374249 99394816 + CALU chr7 128739292 128773400 + CDT1 chr16 88803789 88809258 + ENSA chr1 150600851 150629612 - ERG28 chr14 75649791 75660876 - GTSE1 chr22 46296870 46330810 + KDSR chr18 63327726 63367228 - NONO chrX 71283192 71301168 + PALLD chr4 168497052 168928457 + PURB chr7 44876299 44885530 - RAB14 chr9 121178133 121223014 - TANC2 chr17 63009556 63427699 + TRIM33 chr1 114392790 114511203 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001025 chr2 69565029 69565697 - hsa_circ_0000284 chr11 33307958 33309057 + hsa_circ_0001085 chr2 191765289 191789319 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008738.7 chr19 33207129 33207639 + AC109460.3 chr16 28974804 28990775 + KCNQ1OT1 chr11 2608328 2699994 - LINC00943 chr12 126723412 126749027 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + SDCBP2-AS1 chr20 1325405 1378735 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.